- Home
- SRZN vs ADAG Comparison
SRZN vs ADAG Comparison
Compare SRZN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | ADAG |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | China |
| Employees | 59 | 128 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.6M | 222.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRZN | ADAG |
|---|---|---|
| Price | $17.43 | $3.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $38.00 | $8.25 |
| AVG Volume (30 Days) | 172.1K | ★ 187.3K |
| Earning Date | 05-08-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,477,000.00 | N/A |
| Revenue This Year | $75.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.39 | $1.44 |
| 52 Week High | $35.00 | $4.85 |
Technical Indicators
Market Signals| Indicator | SRZN | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 23.83 | 41.67 |
| Support Level | N/A | $3.23 |
| Resistance Level | $23.55 | $3.53 |
| Average True Range (ATR) | 1.29 | 0.27 |
| MACD | -0.42 | -0.02 |
| Stochastic Oscillator | 4.15 | 34.20 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.